Global pharmaceutical major Lupin Limited has announced the launch of an authorized generic version of Ravicti® (Glycerol Phenylbutyrate) Oral Liquid, 1.1g/mL, in the United States, marking another milestone in its commitment to expanding access to critical care therapies.

The medication is indicated for the chronic management of patients with Urea Cycle Disorders (UCDs)—a group of rare genetic conditions that affect the body’s ability to remove ammonia from the bloodstream. It is prescribed for individuals who cannot be adequately managed through dietary protein restriction and/or amino acid supplementation alone.

With this launch, Lupin strengthens its U.S. portfolio in the rare metabolic disorder segment, providing patients and healthcare providers with a cost-effective and reliable alternative to the reference listed drug Ravicti®.

The company continues to reinforce its presence in complex generics and specialty therapeutics, focusing on improving accessibility to essential treatments for patients worldwide.